Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 347867, 10 pages
http://dx.doi.org/10.1155/2015/347867
Research Article

Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival

1Physiopathology of Human Reproduction, IRCCS A.O.U. San Martino-IST, 16132 Genoa, Italy
2Laboratory of Biotherapy, IRCCS A.O.U. San Martino-IST, 16132 Genoa, Italy
3Laboratory of Oncology, IRCCS Istituto Giannina Gaslini, 16148 Genoa, Italy
4Oncology Unit, IRCCS Istituto Giannina Gaslini, 16148 Genoa, Italy
5Epidemiology, Biostatistics and Committees Unit, IRCCS Istituto Giannina Gaslini, 16148 Genoa, Italy
6Neuroblastoma Laboratory, Pediatric Research Institute, Fondazione Città della Speranza, 35127 Padua, Italy

Received 10 July 2014; Revised 12 January 2015; Accepted 14 January 2015

Academic Editor: Mohammad Owais

Copyright © 2015 Sara Stigliani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N.-K. V. Cheung and M. A. Dyer, “Neuroblastoma: developmental biology, cancer genomics and immunotherapy,” Nature Reviews Cancer, vol. 13, no. 6, pp. 397–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. M. Brodeur, J. Pritchard, F. Berthold et al., “Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment,” Journal of Clinical Oncology, vol. 11, no. 8, pp. 1466–1477, 1993. View at Google Scholar · View at Scopus
  3. S. L. Cohn, A. D. J. Pearson, W. B. London et al., “The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 289–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. V. F. Viprey, W. M. Gregory, M. V. Corrias et al., “Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1074–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Vermeulen, K. de Preter, A. Naranjo et al., “Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study,” The Lancet Oncology, vol. 10, no. 7, pp. 663–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Takita, M. Ishii, S. Tsutsumi et al., “Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma,” Genes Chromosomes and Cancer, vol. 40, no. 2, pp. 120–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Schramm, J. H. Schulte, L. Klein-Hitpass et al., “Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling,” Oncogene, vol. 24, no. 53, pp. 7902–7912, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ohira, S. Oba, Y. Nakamura et al., “Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas,” Cancer Cell, vol. 7, no. 4, pp. 337–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Oberthuer, B. Hero, F. Berthold et al., “Prognostic impact of gene expression-based classification for neuroblastoma,” Journal of Clinical Oncology, vol. 28, no. 21, pp. 3506–3515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Hiyama, K. Hiyama, H. Yamaoka, T. Sueda, C. P. Reynolds, and T. Yokoyama, “Expression profiling of favorable and unfavorable neuroblastomas,” Pediatric Surgery International, vol. 20, no. 1, pp. 33–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. Q.-R. Chen, Y. K. Song, J. S. Wei et al., “An integrated cross-platform prognosis study on neuroblastoma patients,” Genomics, vol. 92, no. 4, pp. 195–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Asgharzadeh, R. Pique-Regi, R. Sposto et al., “Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification,” Journal of the National Cancer Institute, vol. 98, no. 17, pp. 1193–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G. J. Adema, “The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells,” Immunology, vol. 138, no. 2, pp. 105–115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Galon, H. K. Angell, D. Bedognetti, and F. M. Marincola, “The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures,” Immunity, vol. 39, no. 1, pp. 11–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. R. C. Seeger, “Immunology and immunotherapy of neuroblastoma,” Seminars in Cancer Biology, vol. 21, no. 4, pp. 229–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Facchetti, I. Prigione, F. Ghiotto, P. Tasso, A. Garaventa, and V. Pistoia, “Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma,” Cancer Immunology, Immunotherapy, vol. 42, no. 3, pp. 170–178, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Asgharzadeh, J. A. Salo, L. Ji et al., “Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3525–3532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Song, S. Asgharzadeh, J. Salo et al., “Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1524–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Gowda, K. Godder, M. Kmieciak et al., “Distinct signatures of the immune responses in low risk versus high risk neuroblastoma,” Journal of Translational Medicine, vol. 9, no. 1, article 170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Tilak, S. Sherawat, S. Agarwala, R. Gupta, S. Vishnubhatla, and S. Bakhshi, “Circulating t-regulatory cells in neuroblastoma: a pilot prospective study,” Pediatric Hematology and Oncology, vol. 31, no. 8, pp. 717–722, 2014. View at Publisher · View at Google Scholar
  21. F. Martin, S. Ladoire, G. Mignot, L. Apetoh, and F. Ghiringhelli, “Human FOXP3 and cancer,” Oncogene, vol. 29, no. 29, pp. 4121–4129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. J. DeLeeuw, S. E. Kost, J. A. Kakal, and B. H. Nelson, “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature,” Clinical Cancer Research, vol. 18, no. 11, pp. 3022–3029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. M. Carlson, A. de Geer, B. Sveinbjornsson et al., “The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes,” OncoImmunology, vol. 2, Article ID e23618, 2013. View at Google Scholar
  24. N. Gagliani, C. F. Magnani, S. Huber et al., “Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells,” Nature Medicine, vol. 19, no. 6, pp. 739–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Haupt, A. Garaventa, C. Gambini et al., “Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian neuroblastoma registry,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2331–2338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Scaruffi, S. Stigliani, S. Moretti et al., “Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma,” BMC Cancer, vol. 9, article 441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. V. F. Viprey, M. V. Corrias, B. Kagedal et al., “Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET,” European Journal of Cancer, vol. 43, no. 2, pp. 341–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Badoual, S. Hans, J. Rodriguez et al., “Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers,” Clinical Cancer Research, vol. 12, no. 2, pp. 465–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Salama, M. Phillips, F. Grieu et al., “Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Kmieciak, M. Gowda, L. Graham et al., “Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function,” Journal of Translational Medicine, vol. 7, article 89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Wang, A. Ioan-Facsinay, E. I. H. van der Voort, T. W. J. Huizinga, and R. E. M. Toes, “Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells,” European Journal of Immunology, vol. 37, no. 1, pp. 129–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. Allan, S. Q. Crome, N. K. Crellin et al., “Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production,” International Immunology, vol. 19, no. 4, pp. 345–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Rigo, M. V. Corrias, A. M. Orengo et al., “Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity,” Cancer Immunology, Immunotherapy, vol. 63, no. 5, pp. 501–511, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Croce, M. V. Corrias, A. M. Orengo et al., “Transient depletion of CD4+ T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice,” International Journal of Cancer, vol. 127, no. 5, pp. 1141–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Jing, J. A. Gershan, and B. D. Johnson, “Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory,” Blood, vol. 113, no. 18, pp. 4449–4457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Jing, X. Yan, W. H. D. Hallett, J. A. Gershan, and B. D. Johnson, “Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma,” Blood, vol. 117, no. 25, pp. 6952–6962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. V. Corrias, M. Occhino, M. Croce et al., “Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression,” Tissue Antigens, vol. 57, no. 2, pp. 110–117, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Castriconi, A. Dondero, M. V. Corrias et al., “Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction,” Cancer Research, vol. 64, no. 24, pp. 9180–9184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Ponzoni, F. Guarnaccia, M. V. Corrias, and P. Cornaglia-Ferraris, “Uncoordinate induction and differential regulation of HLA class-I and class-II expression by γ-interferon in differentiating human neuroblastoma cells,” International Journal of Cancer, vol. 55, no. 5, pp. 817–823, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Engelmann, K. Farkas, J. Kis et al., “Characterization of human invariant natural killer T cells expressing FoxP3,” International Immunology, vol. 23, no. 8, pp. 473–484, 2011. View at Publisher · View at Google Scholar · View at Scopus